Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11160%2F25%3A10504648" target="_blank" >RIV/00216208:11160/25:10504648 - isvavai.cz</a>
Alternative codes found
RIV/68407700:21340/25:00381206
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=.pP9267U8n" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=.pP9267U8n</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.nucmedbio.2025.108998" target="_blank" >10.1016/j.nucmedbio.2025.108998</a>
Alternative languages
Result language
angličtina
Original language name
Terbium-161 in nuclear medicine: Preclinical and clinical progress in comparison with lutetium-177
Original language description
The use of new radiopharmaceuticals labeled with lutetium-177 represents a successful translation of experimental results into clinical practice. Recent experimental data suggests that terbium-161 might well follow the example of lutetium-177 regarding applicability in nuclear medicine. Similarly to lutetium-177, the terbium-161 emits beta particles and gamma-radiation, although terbium-161 emits short-ranged conversion and Auger electrons, creating an effect that may eliminate smaller tumor metastases more effectively than lutetium-177. Terbium-161 may exert a higher radiobiological effect in the target tissues in comparison with lutetium-177, a difference which makes possible a reduction in the doses of radioactivity administered. Further, due to the similar chemical properties of lutetium-177 and terbium-161, similar radiolabeling techniques can be used. The differences found in preclinical experiments on radiotoxicity of the counterparts seem to be minor. Despite intensive progress, the number of preclinical studies on 161Tb-labeled agents is still not comparable to studies on lutetium-177. Clinical trials with 161Tb-labeled radiopharmaceuticals focused on the treatment of prostate cancer and selected neuroendocrine tumors have already begun, although none of them have been completed yet.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
<a href="/en/project/NU23-08-00214" target="_blank" >NU23-08-00214: Development of terbium-161-labelled biomolecules as theranostic tools in nuclear medicine</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Nuclear Medicine and Biology
ISSN
0969-8051
e-ISSN
1872-9614
Volume of the periodical
144-145
Issue of the periodical within the volume
May-June
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
108998
UT code for WoS article
001429337000001
EID of the result in the Scopus database
2-s2.0-85217897336